Document is current
Any future updates will be listed below
-
Authors
Åslund, Andreas K. O.
Vandebriel, Rob J.
Caputo, Fanny
de Jong, Wim H.
Delmaar, Christiaan
Hyldbakk, Astrid
Rustique, Emilie
Schmid, Ruth
Snipstad, Sofie
Texier, Isabelle
Vernstad, Kai
Borgos, Sven Even F. https://orcid.org/0000-0002-6222-9252
-
Funding
Funding for this research was provided by:
Horizon 2020 (761104)
SINTEF
- License Information
-
More Information
Article History
Accepted: 28 March 2022
First Online: 15 April 2022
Declarations
:
: The research did not involve human subjects. All institutional and national guidelines for the care and use of laboratory animals were followed.
: Not applicable.
: R.S. is co-inventor of a patent describing the use of inhibitors during preparation of drug-loaded PACA nanoparticles (R. Schmid, P. Molesworth, Y. Mørch, E. Sulheim, H. Johnsen, <i>Nanoparticles. PCT/EP2019/072612 (2018)</i>) and of a patent describing the use of PACA with Cbz for cancer treatment (<i>Y. Mørch, R. Schmid, E. Sulheim, P. Stenstad, H. Johnsen, K. Sandvig, G. Mælandsmo, T. Skotland, poly(alkyl cyanoacrylate) nanoparticles for use in treatment of cancer. PCT/EP2019057678 (2019)</i>).The authors declare no other competing interests.
